Lung cancer has entered an era of personalized therapy with treatment based on histologic subtypes (adenocarcinoma versus squamous) and the presence of molecular markers [epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)]. The gene discussed is EGFR; the disease is adenocarcinoma.